Oncology Data Advisor
448 episodes — Page 8 of 9
Exploring Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer: Josep Tabernero, MD, PhD
At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.
Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD
At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).
Additional Advances in Chemotherapy-Induced Neutropenia Research and Clinical Trials
In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health’s CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educating patients who are at risk for chemotherapy-induced neutropenia and shares some of the therapeutic developments in both prevention and management that are coming down the pipeline in the near future. Click here to view and claim credit for New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/new-cme/44-policies/503-i3health-com-cin
Multiple Myeloma Trials and Quality News Reporting With Manni Mohyuddin, MBBS
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD
In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia. Click here to view and claim credit for Therapy of B-Cell Acute Lymphoblastic Leukemia: an Evolving Landscape, an accredited CME/NCPD/CPE activity provided by i3 Health: https://i3health.com/odacon-all
Additional Advances in Squamous NSCLC Research and Clinical Trials With Mark Kris, MD
In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.
Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD
Visit https://i3health.com/relapsed-refractory-multiple-myeloma to book a live or virtual meeting at your own institution and hear more expert perspectives from Dr. Kumar or other esteemed multiple myeloma faculty! Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.
Additional Advances in Multiple Myeloma Research and Clinical Trials: Sarah Holstein, MD, PhD
Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about what to look forward to from this year's ASH Annual Meeting.
Highlights from the San Antonio Breast Cancer Symposium
Dr. Jason Mouabbi of the MD Anderson Cancer Center sits down with Oncology Data Advisor to go over updates and highlights from the recent San Antonio Breast Cancer Symposium (SABCS).
CLL Society, a Valuable Resource for Patients and the Health Care Team: Brian Koffman, MD
In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them.
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ
In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.
Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD
In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford Healthcare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.
Additional Advances in Waldenstrom Macroglobulinemia Research and Clinical Trials: Morie Gertz, MD
In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the May Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia (WM) session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.
Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. To complete the activity and claim free CME/NCPD, visit: https://i3health.com/mf
Understanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel Rubinstein
Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.
Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.
Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer.
Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD
In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent’s Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them.
Breast Cancer Is Not Just One Disease: Lobular Breast Cancer Research With Jason Mouabbi, MD
Understanding the various subtypes of breast cancer is critical, as treatment selection and potential outcomes depend heavily on subtype. In this latest Oncology Data Advisor interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, an Assistant Professor at the University of Texas MD Anderson Cancer Center, sheds light on lobular breast, an often-understudied subtype. Dr. Mouabbi shares his passion for raising awareness about lobular breast cancer and his goal of better understanding it at the genomic level to develop novel therapeutic options.
Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes: Rahul Banerjee and Ajay Major
Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.
Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine: Blanca Ledezma, MSN, NP
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.
Caring for Patients Receiving CAR T-Cell Therapy
In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.
Addressing Clinical Trial Accrual of Minority Patients With Donna Catamero, NP
At the recent International Myeloma Society (IMS) Annual Meeting, Donna Catamero, NP, Associate Director of Myeloma Translational Research at Mount Sinai Hospital, presented her abstract regarding increasing clinical trial accrual of minority patients. In this interview, Ms. Catamero discusses her presentation, the disproportionate burden that minority patients experience, and why she believes the health care team should take action to create an equal space for everyone in the clinic.
Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP
At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.
No One Left Alone: Taking the First Steps to Address Cancer Disparities With Kashyap Patel, MD
At the recent International Myeloma Society (IMS) Annual Meeting, Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates and President of the Community Oncology Alliance, spoke about practical solutions for addressing disparities in multiple myeloma in the United States. In this follow-up interview with Oncology Data Advisor, Dr. Patel digs deep into the multifaceted factors that contribute to cancer disparities and shares his pioneering work that aims to ensure that every patient with cancer receives equitable access to care.
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.
The Future of MRD in Multiple Myeloma Treatment Decision Making
In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.
Increasing Medical Student Confidence When Treating LGBTQIA+ Patients
Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities.
Understanding the Current Landscape of Chemotherapy-Induced Neutropenia
In this interview, Maura Abbott describes the current landscape of chemotherapy-induced neutropenia and the activity she co-led earlier this year.
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.
Tackling Violence and Stigmatization to Decrease Disparities for Transgender Patients: Ash Alpert
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies’ results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.
Discussing Patient-Reported Hope in Early Phase Clinical Trials With Debra Lundquist, PhD, RN
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Debra Lundquist, PhD, RN, of Massachusetts General Hospital and colleagues presented their poster that sought to bridge the gap between recent advances in individual therapy which led to improved outcomes and a better understanding of patient-reported hope, quality of life, symptom burden, and coping mechanisms in early phase clinical trial participants.
Remote Symptom Monitoring and Management: Kathi Mooney, PhD, RN
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Project Koru and Cancer Survivorship: Beth Peck
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Lobular Breast Cancer Histology and Research: Jason Mouabbi, MD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Patritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Ocular Oncology and the Personalized Approach: Dan Gombos, MD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
The Nurse's Role in Oncology Research and Quality Care: Jeannine Brant, PhD, APRN
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
HRAS Mutations in Breast Cancer: Sam Kareff, MD, MPH
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Perspectives on the Most Exciting Research at ASCO: Navdeep Dehar, MD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Thriving Beyond the Cancer Diagnosis: Colin Ferro
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Neuroblastoma Risk Stratification and Research: Wendy London, PhD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Transforming Cancer Care Delivery and Patient Experiences Through Technology: David Penberthy, MD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Breast Cancer Prevention and Disparities: Jessica Jones, MD
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!